+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Endocrinology Drugs Market - Global Forecast 2026-2032- Product Image
Endocrinology Drugs Market - Global Forecast 2026-2032- Product Image
New

Endocrinology Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 188 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5967946
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Endocrinology Drugs Market is undergoing significant transformation as clinical innovation, regulatory change, and patient-centered care reshape strategies for industry leaders. Decision-makers face evolving opportunities to advance clinical practices and market performance in this complex landscape.

Market Snapshot: Endocrinology Drugs Market Growth and Outlook

The global Endocrinology Drugs Market grew from USD 65.43 billion in 2025 to USD 70.12 billion in 2026 and is projected to register a CAGR of 7.67%, reaching USD 109.78 billion by 2032. This sustained growth is driven by rising chronic disease rates, innovation in targeted therapeutics, and a growing emphasis on value-based healthcare frameworks. Senior leaders are responding to increased complexity by optimizing supply and commercial pathways to align with evolving patient and payer needs.

Scope & Segmentation

  • Therapy Areas: Markets span adrenal disorders, diabetes, growth and pituitary disorders, osteoporosis, and thyroid conditions—offering diverse opportunities for portfolio differentiation across subspecialties.
  • Drug Classes: Innovation and adoption cover calcitonin peptides, growth hormone therapies, insulin, oral antidiabetics, oral hypoglycemics, and parathyroid hormone analogs—addressing multiple modes of disease management and advancing pharmacological options.
  • Modes of Administration: Commercial strategies increasingly support inhalable, injectable, and oral drugs, optimizing patient adherence and broadening treatment accessibility.
  • Patient Age Groups: The sector covers adult, geriatric, and pediatric segments, requiring tailored drug development and access approaches to meet distinct clinical requirements.
  • Distribution Channels: Hospital, online, and retail pharmacies support access through varied dispensing frameworks, adapting to changing patient behavior and regulatory landscapes.
  • Geographic Regions: The market serves the Americas, Europe, Middle East and Africa, and Asia-Pacific, each presenting unique regulatory, payer, and infrastructure considerations for stakeholders.
  • Technologies: Adoption of biologics, biosimilars, digital therapeutics, remote monitoring, modular manufacturing, and advanced delivery devices is accelerating, promoting efficiency, and supporting patient engagement objectives.

Key Takeaways: Strategic Insights for Decision-Makers

  • Precision medicine and biologic therapies shift care models, enabling more individualized treatment approaches for complex endocrine diseases and driving product pipeline differentiation.
  • Integration of digital tools, including remote monitoring and new care models, supports improved adherence, data accuracy, and compliance with evolving regulatory expectations.
  • Partnerships with contract manufacturing organizations and technology collaborators are now essential for increasing market agility, reducing time-to-market, and managing supply chain vulnerabilities.
  • Sophisticated access programs and dynamic pricing models address heterogeneous healthcare infrastructure and evolving payer demands, strengthening market positioning amid reimbursement uncertainty.
  • Segment-specific initiatives—by therapy area, age group, or channel—generate clinical and commercial value, helping organizations reach underserved populations more effectively.

Tariff Impact: Supply Chain and Pricing Dynamics

Tariff changes implemented in 2025 have created new supply chain pressures for endocrinology therapies, elevating input costs and leading to broader adoption of nearshoring and dual-sourcing tactics. As a result, producers and payers are actively reassessing both sourcing and pricing mechanisms to assure stable product access. Supplier diversification strategies and evolving contract negotiations, with an emphasis on total care costs and risk-sharing, reflect a shift toward greater resilience and adaptive pricing. Regional regulators respond with more flexible frameworks to stabilize supply and navigate payment complexities.

Methodology & Data Sources

This assessment leverages a mixed-methods approach, gathering primary data from structured interviews alongside in-depth secondary research. The process incorporates clinical expert consultations, scientific literature reviews, regulatory document analysis, and scenario-based validation to ensure commercial and clinical relevance. Rigorous sensitivity and triangulation analyses further support data integrity.

Why This Report Matters

  • Enables alignment across R&D, supply chain, and commercialization functions through clear, actionable strategic guidance that matches current market conditions.
  • Empowers business leaders with scenario-based perspectives for navigating ongoing regulatory shifts and leveraging emerging therapy platforms for regional market entry and access.
  • Supports robust operational planning with practical recommendations on sourcing, differentiation, and partnership structures suited to a diverse marketplace.

Conclusion

Integrated action across research, manufacturing, and market strategy is essential for leadership in the Endocrinology Drugs Market. Focused investment in adaptable offerings and resilient supply models positions organizations for steady performance amid continuous change.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Endocrinology Drugs Market, by Drug Class
8.1. Calcitonin Peptides
8.2. Growth Hormone
8.3. Insulin
8.4. Oral Antidiabetics
8.5. Oral Hypoglycemics
8.6. Parathyroid Hormones & Analogs
9. Endocrinology Drugs Market, by Therapy Area
9.1. Adrenal Disorders
9.2. Diabetes
9.3. Growth Disorders
9.4. Osteoporosis
9.5. Pituitary Disorders
9.6. Thyroid Disorders
10. Endocrinology Drugs Market, by Mode of Administration
10.1. Inhalable
10.2. Injectable
10.3. Oral
11. Endocrinology Drugs Market, by Patient Age Group
11.1. Adult
11.2. Geriatric
11.3. Pediatric
12. Endocrinology Drugs Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Endocrinology Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Endocrinology Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Endocrinology Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Endocrinology Drugs Market
17. China Endocrinology Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. AbbVie Inc.
18.7. Ascendis Pharma A/S
18.8. AstraZeneca PLC
18.9. Bayer AG
18.10. Biocon Limited
18.11. Boehringer Ingelheim International GmbH
18.12. Bristol-Myers Squibb Company
18.13. CHIESI Farmaceutici S.p.A.
18.14. Eli Lilly and Company
18.15. Endo, Inc.
18.16. F. Hoffmann-La Roche Ltd.
18.17. GlaxoSmithKline PLC
18.18. Hanmi Pharm Co., Ltd.
18.19. Ipsen Pharma
18.20. Johnson & Johnson Services, Inc.
18.21. MacroGenics, Inc.
18.22. MannKind Corporation
18.23. Merck & Co., Inc.
18.24. Novartis AG
18.25. Novo Nordisk A/S
18.26. Oramed Pharmaceuticals Inc.
18.27. Pfizer Inc.
18.28. Precigen, Inc.
18.29. Sanofi S.A
18.30. Shenzhen Microchip Biotechnology Co., Ltd.
18.31. Sun Pharmaceutical Industries Limited
18.32. Takeda Pharmaceutical Company Limited
18.33. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 97. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 98. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 100. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 110. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 122. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 123. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 125. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 128. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 129. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 131. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 141. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 143. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 147. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 149. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 152. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 153. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 164. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 165. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
TABLE 166. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 168. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Endocrinology Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Ascendis Pharma A/S
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CHIESI Farmaceutici S.p.A.
  • Eli Lilly and Company
  • Endo, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hanmi Pharm Co., Ltd.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • MacroGenics, Inc.
  • MannKind Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Precigen, Inc.
  • Sanofi S.A
  • Shenzhen Microchip Biotechnology Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages188
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 70.12 Billion
Forecasted Market Value ( USD ) by 2032 $ 109.78 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Endocrinology Drugs Market - Global Strategic Business Report - Product Image

Endocrinology Drugs Market - Global Strategic Business Report

  • Report
  • 288 Pages
  • Global
From
Endocrinology Drugs Market Report 2025 - Product Image

Endocrinology Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Endocrinology Drugs Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Endocrinology Drugs Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Endocrinology Drugs Market 2025-2029 - Product Image

Endocrinology Drugs Market 2025-2029

  • Report
  • 205 Pages
  • Global
From
Human Growth Hormone (HGH) Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033 - Product Image

Human Growth Hormone (HGH) Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033

  • Report
  • 200 Pages
  • Global
From

About the Market

The Endocrinology Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market, which focuses on drugs used to treat endocrine and metabolic disorders. These drugs are used to treat a variety of conditions, including diabetes, thyroid disorders, obesity, and growth hormone deficiency. Endocrinology drugs are typically administered orally, intravenously, or subcutaneously. They can also be administered through inhalation or injection. Endocrinology drugs are typically developed by pharmaceutical companies and are subject to stringent regulatory approval processes. These drugs are often expensive and require ongoing monitoring and management. Some of the major companies in the Endocrinology Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.